NASDAQ: CTKBCytek Biosciences Inc Stock
$3.70+0.05 (+1.37%)
Updated Apr 21, 2025
CTKB Price
$3.70
Fair Value Price
$1.60
Market Cap
$473.96M
52 Week Low
$3.27
52 Week High
$7.63
P/E
-74x
P/B
1.2x
P/S
4.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$200.45M
Earnings
-$6.02M
Gross Margin
55.4%
Operating Margin
-0.23%
Profit Margin
-3%
Debt to Equity
0.26
Operating Cash Flow
$25M
Beta
1.4
Next Earnings
Jun 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CTKB Overview
Cytek Biosciences, Inc. provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. Its core instruments, the Aurora and Northern Lights systems, are spectrum flow cytometers. The company sells its instruments in the U.S. and internationally. Cytek Biosciences was founded in 1992 and is headquartered in Fremont, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTKB's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
B
CTKB
Ranked#47 of 103
Ranked#47 of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.50 | A | |
| $22.62 | A | |
| $13.45 | A |
Be the first to know about important CTKB news, forecast changes, insider trades & much more!
CTKB News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTKB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTKB ($3.70) is overvalued by 130.76% relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTKB ($3.70) is not significantly undervalued (130.76%) relative to our estimate of its Fair Value price of $1.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTKB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTKB due diligence checks available for Premium users.
Valuation
CTKB fair value
Fair Value of CTKB stock based on Discounted Cash Flow (DCF)
Price
$3.70
Fair Value
$1.60
Overvalued by
130.76%
CTKB ($3.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTKB ($3.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTKB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CTKB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-74x
Industry
40.34x
Market
27.14x
CTKB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
3.74x
CTKB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTKB's financial health
Profit margin
Revenue
$57.5M
Net Income
$9.6M
Profit Margin
16.8%
CTKB's Earnings (EBIT) of -$461.00k... subscribe to Premium to read more.
Interest Coverage Financials
CTKB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$499.5M
Liabilities
$103.8M
Debt to equity
0.26
CTKB's short-term assets ($396.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTKB's short-term assets ($396.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTKB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTKB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.0M
Investing
-$63.4M
Financing
-$3.6M
CTKB's operating cash flow ($25.38M)... subscribe to Premium to read more.
Debt Coverage Financials
CTKB vs Medical Device Stocks
Cytek Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.